# Biospecimens and Patient Registry

> **NIH NIH P50** · MAYO CLINIC ROCHESTER · 2022 · $185,323

## Abstract

ABSTRACT – BIOSPECIMENS AND PATIENT REGISTRY CORE (CORE B)
The goal of the Biospecimens and Patient Registry Core (Core B) is to provide the Mayo Clinic SPORE in 
Ovarian Cancer investigators with high quality patient clinical data, DNA, RNA, blood products, and tissues 
(normal and malignant) from consented patients with ovarian, fallopian tube, or primary peritoneal carcinoma 
and suitable controls, and to make these resources available for future studies. The Mayo Clinic has a strong 
tradition of ethically sound support of research that links tissue acquisition and patient data records. Paraffin 
embedded tissues, histological slides, and associated patient charts from surgeries performed since the first 
decade of the 1900's are maintained in Mayo’s Tissue Registry and the Mayo Archives. Core B interacts with 
i) the Pathology Research Core of the Mayo Clinic Cancer Center, which provides expertise, collaborative 
support, and service for immunohistochemistry, in situ hybridization, tissue microarray construction, and digital 
imaging; ii) the Biospecimens Accessioning and Processing Core, which is the primary site of accessioning 
and standardized processing of blood and frozen tissue collected explicitly for research from all three Mayo 
sites; and iii) the Cytogenetics Core, which has expertise in establishing, validating, and scoring fluorescence 
in situ hybridization (FISH) studies. Core B is integrated with these existing tissue-oriented Cancer Center 
shared resources and other scientific Cores of this SPORE to provide a coordinated, centralized, dedicated 
program for standardized collection, accessioning, processing, morphologic classification, and genomic 
annotation of biospecimens so that these can be studied in the context of patient data from fully consented 
patients. Thorough clinical annotation is required to maximize the potential use of tissue specimens in 
translational research; therefore, risk factor questionnaires, clinical records, and pathology review are 
incorporated into the Core. Research services, including pathologic review of tumor histology, tumor sectioning 
and quality control, blood processing, construction of tissue microarrays (TMAs), immunohistochemistry (IHC), 
and FISH, will be provided as needed to SPORE investigators. Core B is closely coordinated with the 
Biostatistics and Bioinformatics Core (Core C) to provide seamless linkage of clinical annotation with research 
specimens for data management and analyses. In Years 6-10 of Mayo Clinic SPORE in Ovarian Cancer 
funding, Core B distributed 4326 ovarian tumor tissues, 511 TMA slides, and 3628 germline DNA samples. In 
addition, Core B undertook a systematic evaluation of common ovarian cancer susceptibility genes in all stored 
cancer specimens and successfully collaborated with a stem cell biologist, new to ovarian cancer research, to 
generate a novel biospecimen—benign Fallopian tube organoids from women at average risk and high risk 
(BRCA1/2,...

## Key facts

- **NIH application ID:** 10452717
- **Project number:** 5P50CA136393-12
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** MARK E SHERMAN
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $185,323
- **Award type:** 5
- **Project period:** 2009-07-01 → 2026-08-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10452717

## Citation

> US National Institutes of Health, RePORTER application 10452717, Biospecimens and Patient Registry (5P50CA136393-12). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10452717. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*